PT  - JOURNAL ARTICLE
AU  - William J. Bradshaw
AU  - Jonathan H. Huggins
AU  - Alun L. Lloyd
AU  - Kevin M. Esvelt
TI  - The feasibility of targeted test-trace-isolate for the control of SARS-CoV-2 variants
AID  - 10.1101/2021.01.11.21249612
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.11.21249612
4099  - http://medrxiv.org/content/early/2021/01/28/2021.01.11.21249612.short
4100  - http://medrxiv.org/content/early/2021/01/28/2021.01.11.21249612.full
AB  - The SARS-CoV-2 variant B.1.1.7 reportedly exhibits substantially higher transmission than the ancestral strain and may generate a major surge of cases before vaccines become widely available, while the P.1 and B.1.351 variants may be equally transmissible and also resist vaccines. All three variants can be sensitively detected by RT-PCR due to an otherwise rare del11299-11296 mutation in orf1ab; B.1.1.7 can also be detected using the common TaqPath kit. Testing, contact tracing, and isolation programs overwhelmed by SARS-CoV-2 could slow the spread of the new variants, which are still outnumbered by tracers in most countries. However, past failures and high rates of mistrust may lead health agencies to conclude that tracing is futile, dissuading them from redirecting existing tracers to focus on the new variants. Here we apply a branching-process model to estimate the effectiveness of implementing a variant-focused testing, contact tracing, and isolation strategy with realistic levels of performance. Our model indicates that bidirectional contact tracing can substantially slow the spread of SARS-CoV-2 variants even in regions where a large fraction of the population refuses to cooperate with contact tracers or to abide by quarantine and isolation requests.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by gifts from the Reid Hoffman Foundation and the Open Philanthropy Project (to K.M.E.) and cluster time granted by the COVID-19 HPC consortium (MCB20071 to K.M.E.). A.L.L. is supported by the Drexel Endowment (NC State University) and by the award CDC U01CK000587-01M001 from the US Centers for Disease Control and Prevention. The funders had no role in the research, writing, or decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No experiments involving human subjects were performed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode Availability: Code for configuring and running the model is publicly available at https://github.com/willbradshaw/covid-bidirectional-tracing https://github.com/willbradshaw/covid-bidirectional-tracing